Evommune Announces Its Phase 2b Study Of EVO756 Oral Antagonist Failed To Meet Primary Endpoint Of Average Change In Participant's Urticaria Activity Score Over 7 Days At 12 Weeks

Loading news article.

Evommune Announces Its Phase 2b Study Of EVO756 Oral Antagonist Failed To Meet Primary Endpoint Of Average Change In Participant's Urticaria Activity Score Over 7 Days At 12 Weeks | WAPE

Evommune Announces Its Phase 2b Study Of EVO756 Oral Antagonist Failed To Meet Primary Endpoint Of Average Change In Participant's Urticaria Activity Score Over 7 Days At 12 Weeks

Article summary

Related companies

Comments —